File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Sequential therapy with ranibizumab and dexamethasone intravitreal implant is better than dexamethasone monotherapy for macular oedema due to retinal vein occlusion

TitleSequential therapy with ranibizumab and dexamethasone intravitreal implant is better than dexamethasone monotherapy for macular oedema due to retinal vein occlusion
Authors
Issue Date2015
Citation
British Journal of Ophthalmology, 2015, v. 99 n. 2, p. 210-214 How to Cite?
AbstractPURPOSE: To evaluate the efficacy and safety of sequential therapy with ranibizumab followed by dexamethasone intravitreal implant compared with dexamethasone monotherapy for macular oedema (MO) secondary to retinal vein occlusion (RVO). METHODS: In this retrospective interventional study, the medical records of subjects with MO due to RVO who received either ranibizumab followed by dexamethasone intravitreal implant (Group 1) or dexamethasone-implant monotherapy (Group 2) were included. Primary outcome was the proportion of subjects who exhibited best-corrected visual acuity (VA) gain and resolution of MO within 6 months. RESULTS: Thirty-three eyes were included (17 in Group 1, 16 in Group 2). More subjects in Group 1 exhibited a VA gain of at least 0.5 (LogMAR units hereafter) than Group 2 (29% vs 0%, p=0.044). The speed of VA gain was greater in Group 1 (1.4+/-0.8 months vs 2.7+/-1.4 months, p=0.020). MO was controlled in more subjects in Group 1 at all measured time intervals, and this difference was statistically significant at 3 months and 4 months. Subjects with branch RVO experienced VA gain more rapidly if they were from Group 1 (p=0.023). CONCLUSIONS: Sequential therapy was found to be more effective than dexamethasone monotherapy in treating MO due to RVO.
Persistent Identifierhttp://hdl.handle.net/10722/208471
ISSN
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorIu, LPen_US
dc.contributor.authorZhao, Pen_US
dc.contributor.authorYeung, IYen_US
dc.contributor.authorFung, NSen_US
dc.contributor.authorLee, WYJen_US
dc.contributor.authorWong, RLen_US
dc.contributor.authorChong, Ven_US
dc.contributor.authorWong, IYen_US
dc.date.accessioned2015-03-11T07:06:14Z-
dc.date.available2015-03-11T07:06:14Z-
dc.date.issued2015en_US
dc.identifier.citationBritish Journal of Ophthalmology, 2015, v. 99 n. 2, p. 210-214en_US
dc.identifier.issn1468-2079en_US
dc.identifier.urihttp://hdl.handle.net/10722/208471-
dc.description.abstractPURPOSE: To evaluate the efficacy and safety of sequential therapy with ranibizumab followed by dexamethasone intravitreal implant compared with dexamethasone monotherapy for macular oedema (MO) secondary to retinal vein occlusion (RVO). METHODS: In this retrospective interventional study, the medical records of subjects with MO due to RVO who received either ranibizumab followed by dexamethasone intravitreal implant (Group 1) or dexamethasone-implant monotherapy (Group 2) were included. Primary outcome was the proportion of subjects who exhibited best-corrected visual acuity (VA) gain and resolution of MO within 6 months. RESULTS: Thirty-three eyes were included (17 in Group 1, 16 in Group 2). More subjects in Group 1 exhibited a VA gain of at least 0.5 (LogMAR units hereafter) than Group 2 (29% vs 0%, p=0.044). The speed of VA gain was greater in Group 1 (1.4+/-0.8 months vs 2.7+/-1.4 months, p=0.020). MO was controlled in more subjects in Group 1 at all measured time intervals, and this difference was statistically significant at 3 months and 4 months. Subjects with branch RVO experienced VA gain more rapidly if they were from Group 1 (p=0.023). CONCLUSIONS: Sequential therapy was found to be more effective than dexamethasone monotherapy in treating MO due to RVO.en_US
dc.languageengen_US
dc.relation.ispartofBritish Journal of Ophthalmologyen_US
dc.titleSequential therapy with ranibizumab and dexamethasone intravitreal implant is better than dexamethasone monotherapy for macular oedema due to retinal vein occlusionen_US
dc.typeArticleen_US
dc.identifier.emailLee, WYJ: jackylee@hku.hken_US
dc.identifier.authorityLee, WYJ=rp01498en_US
dc.identifier.doi10.1136/bjophthalmol-2014-305661en_US
dc.identifier.pmid25138756-
dc.identifier.scopuseid_2-s2.0-84921553217-
dc.identifier.hkuros233165-
dc.identifier.volume99en_US
dc.identifier.issue2en_US
dc.identifier.spage210en_US
dc.identifier.epage214en_US
dc.identifier.isiWOS:000348285500014-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats